Lim Soo Soo, Tan Peng Chiong, Sockalingam Jayanthi Karen, Omar Siti Zawiah
Department of Obstetrics and Gynaecology, Maternity Hospital Penang, Penang, Malaysia.
Aust N Z J Obstet Gynaecol. 2008 Feb;48(1):71-7. doi: 10.1111/j.1479-828X.2007.00808.x.
To compare oral celecoxib with oral diclofenac as pain reliever after perineal repair following normal vaginal birth.
One hundred and sixty-four and 165 women, respectively, were randomised to 200 mg celecoxib or to 100 mg diclofenac orally 12 hourly for 24 h after perineal repair. A ten-point visual analog scale (VAS) for pain recorded at one, two, four, eight, 12 and 24 hours at rest and when mobilising was the primary outcome.
Repeated measures analysis of variance showed a larger reduction of VAS pain score at rest with celecoxib compared to diclofenac (P = 0.044). Mean VAS pain score at rest was 2.2 versus 2.7, 2.1 versus 2.5, 1.8 versus 2.2, 1.6 versus 1.6, 1.3 versus 1.4 at one, two, four, eight, 12 and 24 hours, respectively, for celecoxib versus diclofenac. The difference in pain score when mobilising was not significant (P = 0.75). Univariate analyses with the Student's t-test indicated significantly lower pain score at rest only at one, two and four hours with celecoxib. Randomisation to celecoxib was associated with less upper gastrointestinal symptoms reported: 38 of 163 (23.3%) versus 57 of 165 (34.5%) (relative risk 0.67 95% CI 0.48-0.96: P = 0.029) but additional analgesia for breakthrough pain was not significantly different eight of 161 (5.0%) versus 18 of 165 (10.9%) (relative risk 0.46 95% CI 0.20-1.01: P = 0.065).
Celecoxib was associated with a slightly lower VAS pain score at rest and less upper gastrointestinal symptoms were reported when compared to diclofenac.
比较口服塞来昔布与口服双氯芬酸在正常阴道分娩会阴修复术后作为止痛剂的效果。
164名和165名女性分别被随机分配,在会阴修复术后24小时内每12小时口服200毫克塞来昔布或100毫克双氯芬酸。主要观察指标是在静息和活动状态下,于1、2、4、8、12和24小时记录的10分视觉模拟疼痛量表(VAS)评分。
重复测量方差分析显示,与双氯芬酸相比,塞来昔布使静息状态下的VAS疼痛评分降低幅度更大(P = 0.044)。塞来昔布与双氯芬酸相比,在1、2、4、8、12和24小时静息状态下的平均VAS疼痛评分分别为2.2对2.7、2.1对2.5、1.8对2.2、1.6对1.6、1.3对1.4。活动时的疼痛评分差异不显著(P = 0.75)。采用学生t检验的单因素分析表明,仅在1、2和4小时静息状态下,塞来昔布的疼痛评分显著更低。随机分配至塞来昔布组报告的上消化道症状较少:163例中有38例(23.3%),而165例中有57例(34.5%)(相对风险0.67,95%可信区间0.48 - 0.96:P = 0.029),但突破性疼痛的额外镇痛情况无显著差异,161例中有8例(5.0%),而165例中有18例(10.9%)(相对风险0.46,95%可信区间0.20 - 1.01:P = 0.065)。
与双氯芬酸相比,塞来昔布与静息状态下稍低的VAS疼痛评分相关,且报告的上消化道症状较少。